Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

Telix Pharmaceuticals Announces FDA Extends New Drug Application Review Period for Illuccix

23 Sep 2021  |  08:55:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: FDA Extends New Drug Application Review Period for Illuccix

Telix Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA, the Agency) has extended the review period for the Company's New Drug Application (NDA) for its prostate cancer imaging investigational product Illuccix by three months.

Please click here for full details

See more ASX300 News Announcements